New research evaluates clinical trials investigating post-acute COVID-19 syndrome treatment

In a recent article published in Clinical Microbiology and Infection, researchers reviewed all registered trials currently investigating potential treatment options for post-acute coronavirus disease 2019 (COVID-19) syndrome (PACS).

Worldwide Survey of COVID-19–Associated Arrhythmias

Paxlovid May Reduce Risk of Long Covid in Eligible Patients, Study Finds - The New York Times

Long COVID NIH COVID-19 Research

JCM, Free Full-Text

Two Years into the COVID-19 Pandemic: Lessons Learned

Post-acute COVID-19 syndrome

Does BCG vaccination protect against acute respiratory infections and COVID- 19? A rapid review of current evidence - The Centre for Evidence-Based Medicine

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial - The Lancet Respiratory Medicine

Frontiers Long COVID: Clinical characteristics, proposed pathogenesis and potential therapeutic targets

Penn Study Finds Serotonin Reduction Causes Long COVID Symptoms

Full article: Registered clinical trials investigating treatment of long COVID: a scoping review and recommendations for research

Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial - The Lancet Respiratory Medicine

Annual Report to the Nation Part 2 pandemic cancer diagnoses - NCI